Overview

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Status:
Recruiting

Trial end date:
2025-02-01

Target enrollment:
0

Participant gender:
All

Summary

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Escient Pharmaceuticals, Inc

Criteria

Inclusion Criteria:

- Documented history of chronic spontaneous urticaria (CSU) with a UAS7 greater than or
equal to 16 despite stable treatment with H1 antihistamine consistent with standard of
care

- Must be on a stable dose of H1 antihistamine up to 4 times the approved dose per local
treatment guidelines

Exclusion Criteria:

- Urticaria with a clear underlying etiology other than CSU

- Urticaria with a clearly defined or sole trigger (chronic inducible urticaria)

- Other active skin diseases associated with chronic pruritus (eg, atopic dermatitis,
bullous pemphigoid, prurigo nodularis, dermatitis herpetiformis)